Product Information
FETZIMA 20-40 MG TITRATION PAK is a brand product labeled by Allergan, Inc., priced at $17.6066 per EA under NDC 00456220228. Its NADAC has been published 618 times since Nov 19, 2014.
FDA first approved this application on Jul 25, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Allergan, Inc.NDC
00456220228
Classification
Brand
Dosage Form
KIT
Route
ORAL
Effective Date
1/2/2026
Approval Type
New Drug (NDA)
FDA Application
NDA204168FDA Approved
7/25/2013
TE Code
AB
On Market Since
7/25/2013
Price Statistics
The NADAC for FETZIMA 20-40 MG TITRATION PAK has been published 618 times since Nov 19, 2014, and over the history we have for it it has risen 131.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.6066 per EA |
|---|---|
| All-time high | $17.6066 (Sep 30, 2026) |
| All-time low | $7.6146 (Nov 19, 2014) |
| 52-week high | $17.6066 |
| 52-week low | $16.7586 |
| Median price | $13.2673 |
| Average price | $13.1915 |
| Largest weekly change | +15.0% (Jul 8, 2015) |
| Weeks tracked | 618 |
| Tracking since | Nov 19, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LEVOMILNACIPRAN HYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LEVOMILNACIPRAN HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FETZIMA 20-40 MG TITRATION PAK?
The current National Average Drug Acquisition Cost (NADAC) for FETZIMA 20-40 MG TITRATION PAK, manufactured by Allergan, Inc., is $17.6066 per EA (NDC 00456220228), effective Sep 30, 2026.
How has the price of FETZIMA 20-40 MG TITRATION PAK changed over time?
Over the history we have for it, the NADAC for FETZIMA 20-40 MG TITRATION PAK has risen 131.2%. It has been tracked across 618 weekly CMS publications since Nov 19, 2014.
What are the highest and lowest recorded NADAC prices for FETZIMA 20-40 MG TITRATION PAK?
Since Nov 19, 2014, the NADAC for FETZIMA 20-40 MG TITRATION PAK has ranged from a low of $7.6146 (Nov 19, 2014) to a high of $17.6066 (Sep 30, 2026), with a median of $13.2673 per EA.
Are there cheaper alternatives to FETZIMA 20-40 MG TITRATION PAK?
No other NADAC-published product currently shares the active ingredient and strength of FETZIMA 20-40 MG TITRATION PAK in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FETZIMA 20-40 MG TITRATION PAK?
FETZIMA 20-40 MG TITRATION PAK (NDC 00456220228) is labeled by Allergan, Inc., and CMS classifies it as a brand product.